Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...

This interaction prevents the binding of TNFα to its receptors, thereby inhibiting the biological activity of TNFα (a cytokine protein). Prior to initiating Simponi Aria and periodically during ...

The FDA has accepted Alvotech (NASDAQ:ALVO) and Teva's (NYSE:TEVA) Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria.

Simponi, J&J's second biologic to gain approval ... The current clinical pipeline of biologic drugs includes 240 mAbs and 120 proteins in various other categories, including alternative scaffolds ...

Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...

Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...

Extensive analytical characterization of the structural, physicochemical, and biological properties of ... BAT2506 is a proposed biosimilar to Simponi® which is a human IgG1 monoclonal antibody ...

Biologics approved by the Food and Drug Administration (FDA) for managing ulcerative colitis include: Anti-TNF agents, such ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the FDA has ...